Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 5 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Recs

0
Player Avatar tking123 (54.17) Submitted: 6/26/2011 9:20:55 AM : Outperform Start Price: $8.87 EXEL Score: -46.40

Cancer drug will be approved

Featured Broker Partners


Advertisement